Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jun;136(6):939-44.
doi: 10.1007/s00432-009-0736-8. Epub 2009 Nov 28.

Evaluation of Oncotype DX Recurrence Score as a prognostic factor in Japanese women with estrogen receptor-positive, node-negative primary Stage I or IIA breast cancer

Kyoko Yorozuya  1 , Toru Takeuchi, Miwa Yoshida, Yukako Mouri, Junko Kousaka, Kimihito Fujii, Shogo Nakano, Takashi Fukutomi, Kazuo Hara, Shu Ichihara, Yingsong Lin, Shogo Kikuchi
Affiliations

Evaluation of Oncotype DX Recurrence Score as a prognostic factor in Japanese women with estrogen receptor-positive, node-negative primary Stage I or IIA breast cancer

Kyoko Yorozuya et al. J Cancer Res Clin Oncol. 2010 Jun.

Abstract

Purpose: We sought to evaluate the use of the Onco type DX Breast Cancer Assay for identifying candidates for adjuvant therapy in patients with estrogen receptor (ER)-positive, node-negative primary Stage I or IIA breast cancer.

Methods: A retrospective case-control study was conducted on 40 patients who underwent surgery between 2000 and 2008. Cases (n = 10) were patients who had metastases after surgery. Controls (n = 30) were patients who did not develop metastases and were individually matched to their case with respect to age. All patients were analyzed with regard to age, tumor size, histological grade, HER2 status, and the values of Recurrence Score (RS), ER score and PgR score generated by Onco type DX. We also divided the patients into low, intermediate or high-risk groups according to individual RS values.

Results: RS, risk category and histological grade were associated with metastases in patients with ER-positive, node-negative Stage I or IIA breast cancer. However, ER status, tumor size and PgR status were not associated with metastases. Histological grade was associated with RS value and the distribution pattern of risk category (P < 0.001 for each).

Conclusions: Both histological grade and risk-category classification were effective in identifying women at risk of developing distant metastases after initial therapy for ER-positive, node-negative Stage I or IIA breast cancer. These patients may benefit from the addition of adjuvant therapy at diagnosis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
The distribution of the RS value according to the histological grade. P < 0.001
See this image and copyright information in PMC

References

    1. Balan V, Nangia-Makker P, Schwartz AG, Jung YS, Trait L, Hogan V, Raz T, Wang Y, Yang ZQ, Wu GS, Guo Y, Li H, Abrams J, Couch FJ, Lingle WL, Lloyd RV, Ethier SP, Tainsky MA, Raz A (2008) Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study. Cancer Res 68:10045–10050 - PMC - PubMed
    1. Kamo K, Katanoda K, Matsuda T, Marugame T, Ajiki W, Sobue T (2008) Lifetime and age-conditional probabilities of developing or dying of cancer in Japan. Jpn J Clin Oncol 38:571–576 - PubMed
    1. Matsuda T, Marugame T, Katanoda K, Ajiki W, Sobue T, the Japan Cancer Surveillance Research Group (2008) Cancer incidence and incidence rates in Japan in 2002: based on data from 11 population-based cancer registries. Jpn J Clin Oncol 38:641–648 - PubMed
    1. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826 - PubMed
    1. Tsuda H, Akiyama F, Kurosumi M, Sakamoto G, Watanabe T (1999) Monitoring of interobserver agreement in nuclear atypia scoring of node-negative breast carcinomas judged at individual collaborating hospitals in the National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) protocol. Jpn J Clin Oncol 29:413–420 - PubMed

Publication types

MeSH terms